XML 108 R63.htm IDEA: XBRL DOCUMENT v3.24.1
Share-based compensation - Option Activity (Details) - USD ($)
$ / shares in Units, $ in Millions
12 Months Ended
Oct. 02, 2023
Dec. 31, 2023
Dec. 31, 2022
Number of shares      
Options, Beginning balance   2,519,405  
Replacement options issued at asset acquisition   2,472,563  
Options, Granted   4,007,552  
Options, Forfeited   (314,319)  
Options, Expired   (55,670)  
Options, Exercised   (651,240)  
Options, Ending balance   7,978,291 2,519,405
Options, Exercisable   3,151,799  
Weighted Average Exercise price      
Beginning price   $ 9.60  
Replacement options issued at asset acquisition   1.29  
Granted   6.42  
Forfeited   6.67  
Expired   16.59  
Exercised   1.57  
Ending price   6.15 $ 9.60
Exercisable   $ 5.86  
Weighted average remaining contractual term      
Weighted Average Remaining Contractual Term   8 years 7 months 13 days  
Weighted Average Remaining Contractual Term, Exercisable   7 years 6 months 14 days  
Weighted average grant date fair value   $ 6.09 $ 2.65
Intrinsic value, exercisable   $ 21.9  
Intrinsic value, outstanding   45.4  
Intrinsic value, exercised   $ 5.9 $ 0.2
Modification of stock options and recognized $ 0.7    
Morphimmune Inc      
Weighted average remaining contractual term      
Weighted average grant fair value $ 7.55